Coherus Oncology Inc (CHRS) — Titan Protect Analysis

CHRS

Coherus Oncology Inc

Healthcare · ·

$1.45

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$231M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.47

Based on estimated future earnings — lower means cheaper

Rev Growth

+62.0%

Year-over-year revenue change

Profit Margin

397.3%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$7.00

+383% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Coherus Oncology Inc

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investi

https://www.coherus.com

Country: United States Employees: 145 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.373

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0134

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.107

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-6.8%

Historical annualised return based on price data

Max Drawdown

-63.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.02

Moves slightly more than the broader market

52W High

$2.62

45% below the year high

52W Low

$0.71

104% above the year low

Avg Volume

1,286,617

Average daily shares traded — higher means easier to buy and sell

Short Ratio

20.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.42

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

69.16

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

68.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-293.7%

Profit from core operations before interest and tax

Free Cash Flow

$-27,062,876

Negative — the business is spending more than it generates

Revenue (TTM)

$47M

Total revenue over the last 12 months

Net Income

$-172,660,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$12.00

Target Median

$7.00

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go